arGEN-X, Kyowa Hakko Kirin deal

arGEN-X received non-exclusive rights from Kyowa's BioWa Inc. subsidiary to use its Potelligent technology to develop arGEN-X's mAbs to treat cancer and inflammatory disorders. The preclinical mAbs w...